Comparison of different statin therapy to change low-density lipoprotein cholesterol and high-density lipoprotein cholesterol level in Korean patients with and without diabetes

J Clin Lipidol. 2016 May-Jun;10(3):528-537.e3. doi: 10.1016/j.jacl.2015.12.013. Epub 2015 Dec 23.

Abstract

Background: It is difficult to apply the proper intensity of statin for new treatment guidelines in clinical settings because of few data about the statin efficacy in Asians. We conducted a retrospective, observational study to estimate the percentage changes in lipid parameters and glucose induced by different statins.

Methods: We analyzed 3854 patients including those with nondiabetes and diabetes treated at the outpatient clinic between 2003 and 2013 who were statin-naïve and maintained fixed-dose of statin for at least 18 months.

Results: Moderate- and low-intensity statin therapy was effective in reducing low-density lipoprotein cholesterol (LDL-C) to <100 mg/dL (70.3%, 83.0%, and 87.2% of diabetic patients in the low-, moderate-, and high-intensity therapy groups, respectively). The rapid decrease of LDL-C was observed in the first 8 months, and LDL-C-lowering effect was maintained throughout the observation period in even the low-intensity statin group. The effects of statins in elevating high-density lipoprotein cholesterol were similar in each statin groups, except the ezetimibe-simvastatin group (4.5 ± 2.1%) and high-dose atorvastatin groups (9.7 ± 3.3% and 8.7 ± 2.4% for 40 mg and 80 mg of atorvastatin/day, respectively). High-density lipoprotein cholesterol increased less and LDL-C decreased more in diabetes than in nondiabetes. There were no significant changes of fasting glucose after statin use in nondiabetic patients.

Conclusions: Moderate- or low-intensity statin was effective enough in reaching National Cholesterol Education Program Adult Treatment Panel III LDL-C target goals in Koreans. Low-intensity statin showed around 30% LDL-C reduction from the baseline level in Koreans, which is comparable to moderate-intensity statin in new guideline.

Keywords: Diabetes; Dyslipidemias; HDL; Hydroxy methylglutaryl-CoA reductase inhibitors; LDL; Lipoproteins; Statin efficacy; Triglycerides.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Azetidines / pharmacology
  • Azetidines / therapeutic use
  • Blood Glucose / metabolism
  • Cholesterol, HDL / blood*
  • Cholesterol, LDL / blood*
  • Diabetes Complications / blood*
  • Diabetes Complications / drug therapy*
  • Female
  • Glycated Hemoglobin / metabolism
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Male
  • Middle Aged
  • Republic of Korea
  • Retrospective Studies
  • Simvastatin / pharmacology
  • Simvastatin / therapeutic use

Substances

  • Azetidines
  • Blood Glucose
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Glycated Hemoglobin A
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • hemoglobin A1c protein, human
  • Simvastatin